|Bid||107.42 x 1300|
|Ask||107.50 x 800|
|Day's range||106.05 - 107.72|
|52-week range||78.66 - 113.41|
|Beta (5Y monthly)||0.81|
|PE ratio (TTM)||39.54|
|Earnings date||30 Apr 2021|
|Forward dividend & yield||5.20 (4.84%)|
|Ex-dividend date||14 Apr 2021|
|1y target est||122.17|
AbbVie (NYSE: ABBV) and Viatris (NASDAQ: VTRS) -- especially stand out due to their attractive valuations. Which is the better value stock? You might think that neither AbbVie nor Viatris qualifies as value stocks based on their trailing-12-month price-to-earnings (P/E) ratios.
FDA delays decision on Pfizer (PFE), AbbVie (ABBV) and Lilly's (LLY) filings for JAK inhibitor candidates. AstraZeneca's (AZN) COVID-19 vaccine troubles continue.
The Zacks Analyst Blog Highlights: ServiceNow, AbbVie and Apple